{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T02:39:44Z","timestamp":1792118384885,"version":"4.4.0"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,7]],"date-time":"2021-12-07T00:00:00Z","timestamp":1638835200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Heart Journal"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.ahj.2021.11.016","type":"journal-article","created":{"date-parts":[[2021,12,3]],"date-time":"2021-12-03T21:06:15Z","timestamp":1638565575000},"page":"41-50","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":80,"special_numbering":"C","title":["Effects of long-term testosterone treatment on cardiovascular outcomes in men with hypogonadism: Rationale and design of the TRAVERSE study"],"prefix":"10.1016","volume":"245","author":[{"given":"Shalender","family":"Bhasin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8175-2121","authenticated-orcid":false,"given":"A. Michael","family":"Lincoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shehzad","family":"Basaria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5261-7721","authenticated-orcid":false,"given":"Douglas C.","family":"Bauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William E.","family":"Boden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2826-541X","authenticated-orcid":false,"given":"Glenn R.","family":"Cunningham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Davey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Dubcenco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Fukumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher B.","family":"Granger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3889-5001","authenticated-orcid":false,"given":"Vidyasagar","family":"Kalahasti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohit","family":"Khera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6597-0727","authenticated-orcid":false,"given":"Michael G.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa M.","family":"Mitchell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael P.","family":"O'Leary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karol M.","family":"Pencina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9838-3139","authenticated-orcid":false,"given":"Peter J.","family":"Snyder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"Ian M.","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1030-7175","authenticated-orcid":false,"given":"Thomas G.","family":"Travison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathy","family":"Wolski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven E.","family":"Nissen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ahj.2021.11.016_bib0001","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1056\/NEJMp1506632","article-title":"Testosterone and \u201cAge-Related Hypogonadism\u201d\u2013FDA Concerns","volume":"373","author":"Nguyen","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2021.11.016_bib0002","unstructured":"US Food and Drug Administration. Joint meeting for Bone, Reproductive and Urologic Drugs Advisory Committee (BRUDAC) and the Drug Safety and Risk Management Advisory Committee (DSARM AC). September 17, 2014."},{"key":"10.1016\/j.ahj.2021.11.016_bib0003","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1210\/jc.2018-00229","article-title":"Testosterone therapy in men with hypogonadism: an endocrine society clinical practice guideline","volume":"103","author":"Bhasin","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ahj.2021.11.016_bib0004","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1001\/jamainternmed.2013.6895","article-title":"Trends in androgen prescribing in the United States, 2001 to 2011","volume":"173","author":"Baillargeon","year":"2013","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.ahj.2021.11.016_bib0005","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1097\/MLR.0000000000000398","article-title":"Ascertainment of testosterone prescribing practices in the VA","volume":"53","author":"Jasuja","year":"2015","journal-title":"Med Care"},{"key":"10.1016\/j.ahj.2021.11.016_bib0006","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1210\/jc.2015-3843","article-title":"A perspective on the evolving landscape in male reproductive medicine","volume":"101","author":"Bhasin","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ahj.2021.11.016_bib0007","article-title":"FDA Drug Safety Communication: FDA cautions about using testosterone products for low testosterone due to aging; requires labeling change to inform of possible increased risk of heart attack and stroke with use","year":"2021","journal-title":"Accessed-"},{"key":"10.1016\/j.ahj.2021.11.016_bib0008","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1111\/acel.12052","article-title":"Testosterone administration inhibits hepcidin transcription and is associated with increased iron incorporation into red blood cells","volume":"12","author":"Guo","year":"2013","journal-title":"Aging Cell"},{"key":"10.1016\/j.ahj.2021.11.016_bib0009","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1210\/jc.2007-1692","article-title":"Effects of graded doses of testosterone on erythropoiesis in healthy young and older men","volume":"93","author":"Coviello","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ahj.2021.11.016_bib0010","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1038\/sj.bjp.0705141","article-title":"The vasodilatory action of testosterone: a potassium-channel opening or a calcium antagonistic action?","volume":"138","author":"Jones","year":"2003","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.ahj.2021.11.016_bib0011","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/S0002-9149(99)00630-X","article-title":"Testosterone enhances flow-mediated brachial artery reactivity in men with coronary artery disease","volume":"85","author":"Ong","year":"2000","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ahj.2021.11.016_bib0012","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1136\/hrt.39.11.1217","article-title":"Effect of testosterone cypionate on postexercise ST segment depression","volume":"39","author":"Jaffe","year":"1977","journal-title":"Br Heart J"},{"key":"10.1016\/j.ahj.2021.11.016_bib0013","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1210\/jc.2003-031492","article-title":"Dose-dependent effects of testosterone on regional adipose tissue distribution in healthy young men","volume":"89","author":"Woodhouse","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ahj.2021.11.016_bib0014","doi-asserted-by":"crossref","first-page":"828","DOI":"10.2337\/dc10-1233","article-title":"Testosterone replacement in hypogonadal men with type 2 diabetes and\/or metabolic syndrome (the TIMES2 study)","volume":"34","author":"Jones","year":"2011","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ahj.2021.11.016_bib0015","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1210\/jc.2017-02545","article-title":"Long-term testosterone administration on insulin sensitivity in older men with low or low-normal testosterone levels","volume":"103","author":"Huang","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ahj.2021.11.016_bib0016","doi-asserted-by":"crossref","first-page":"4254","DOI":"10.1210\/jc.2007-0454","article-title":"Acute sex steroid withdrawal reduces insulin sensitivity in healthy men with idiopathic hypogonadotropic hypogonadism","volume":"92","author":"Yialamas","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ahj.2021.11.016_bib0017","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1530\/EJE-16-0200","article-title":"Relationships between insulin resistance and frailty with body composition and testosterone in men undergoing androgen deprivation therapy for prostate cancer","volume":"175","author":"Cheung","year":"2016","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.ahj.2021.11.016_bib0018","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/S2213-8587(20)30367-3","article-title":"Testosterone treatment to prevent or revert type 2 diabetes in men enrolled in a lifestyle programme (T4DM): a randomised, double-blind, placebo-controlled, 2-year, phase 3b trial","volume":"9","author":"Wittert","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.ahj.2021.11.016_bib0019","doi-asserted-by":"crossref","first-page":"bvaa038","DOI":"10.1210\/jendso\/bvaa038","article-title":"Endogenous testosterone levels and the risk of incident cardiovascular events in elderly men: the MrOS prospective study","volume":"4","author":"Collet","year":"2020","journal-title":"J Endocr Soc"},{"key":"10.1016\/j.ahj.2021.11.016_bib0020","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1016\/j.jacc.2011.07.019","article-title":"High serum testosterone is associated with reduced risk of cardiovascular events in elderly men. The MrOS (Osteoporotic Fractures in Men) study in Sweden","volume":"58","author":"Ohlsson","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2021.11.016_bib0021","doi-asserted-by":"crossref","first-page":"3007","DOI":"10.1210\/jc.2011-1137","article-title":"Clinical review: Endogenous testosterone and mortality in men: a systematic review and meta-analysis","volume":"96","author":"Araujo","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ahj.2021.11.016_bib0022","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1161\/01.CIR.0000125854.51637.06","article-title":"Endogenous sex hormones and progression of carotid atherosclerosis in elderly men","volume":"109","author":"Muller","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2021.11.016_bib0023","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1093\/jnci\/djp404","article-title":"Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer","volume":"102","author":"Keating","year":"2010","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ahj.2021.11.016_bib0024","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/s41591-020-0751-5","article-title":"Using human genetics to understand the disease impacts of testosterone in men and women","volume":"26","author":"Ruth","year":"2020","journal-title":"Nat Med"},{"key":"10.1016\/j.ahj.2021.11.016_bib0025","doi-asserted-by":"crossref","first-page":"e58914","DOI":"10.7554\/eLife.58914","article-title":"Effects of lifelong testosterone exposure on health and disease using Mendelian randomization","volume":"9","author":"Mohammadi-Shemirani","year":"2020","journal-title":"Elife."},{"key":"10.1016\/j.ahj.2021.11.016_bib0026","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1001\/jama.2013.280386","article-title":"Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels","volume":"310","author":"Vigen","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.ahj.2021.11.016_bib0027","doi-asserted-by":"crossref","first-page":"e85805","DOI":"10.1371\/journal.pone.0085805","article-title":"Increased risk of non-fatal myocardial infarction following testosterone therapy prescription in men","volume":"9","author":"Finkle","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.ahj.2021.11.016_bib0028","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1210\/jc.2011-2591","article-title":"Testosterone treatment and mortality in men with low testosterone levels","volume":"97","author":"Shores","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ahj.2021.11.016_bib0029","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1530\/EJE-13-0321","article-title":"Testosterone deficiency is associated with increased risk of mortality and testosterone replacement improves survival in men with type 2 diabetes","volume":"169","author":"Muraleedharan","year":"2013","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.ahj.2021.11.016_bib0030","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1177\/1060028014539918","article-title":"Risk of myocardial infarction in older men receiving testosterone therapy","volume":"48","author":"Baillargeon","year":"2014","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.ahj.2021.11.016_bib0031","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1001\/jama.2016.21043","article-title":"Testosterone treatment and coronary artery plaque volume in older men with low testosterone","volume":"317","author":"Budoff","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.ahj.2021.11.016_bib0032","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1001\/jama.2015.8881","article-title":"Effects of testosterone administration for 3 years on subclinical atherosclerosis progression in older men with low or low-normal testosterone levels: a randomized clinical trial","volume":"314","author":"Basaria","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.ahj.2021.11.016_bib0033","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/1741-7015-11-108","article-title":"Testosterone therapy and cardiovascular events among men: a systematic review and meta-analysis of placebo-controlled randomized trials","volume":"11","author":"Xu","year":"2013","journal-title":"BMC Med"},{"key":"10.1016\/j.ahj.2021.11.016_bib0034","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1517\/14740338.2014.950653","article-title":"Cardiovascular risk associated with testosterone-boosting medications: a systematic review and meta-analysis","volume":"13","author":"Corona","year":"2014","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.ahj.2021.11.016_bib0035","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.amjmed.2016.09.017","article-title":"Cardiovascular risks of exogenous testosterone use among men: a systematic review and meta-analysis","volume":"130","author":"Alexander","year":"2017","journal-title":"Am J Med"},{"key":"10.1016\/j.ahj.2021.11.016_bib0036","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/S2213-8587(16)30215-7","article-title":"Association between exogenous testosterone and cardiovascular events: an overview of systematic reviews","volume":"4","author":"Onasanya","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.ahj.2021.11.016_bib0037","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2016-015284","article-title":"Testosterone therapy in hypogonadal men: a systematic review and network meta-analysis","volume":"7","author":"Elliott","year":"2017","journal-title":"BMJ Open"},{"key":"10.1016\/j.ahj.2021.11.016_bib0038","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.thromres.2018.10.023","article-title":"Testosterone therapy and venous thromboembolism: a systematic review and meta-analysis","volume":"172","author":"Houghton","year":"2018","journal-title":"Thromb Res"},{"key":"10.1016\/j.ahj.2021.11.016_bib0039","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.metabol.2014.05.005","article-title":"Testosterone therapy, thrombosis, thrombophilia, cardiovascular events","volume":"63","author":"Glueck","year":"2014","journal-title":"Metabolism"},{"key":"10.1016\/j.ahj.2021.11.016_bib0040","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1093\/jnci\/djm323","article-title":"Endogenous sex hormones and prostate cancer: acollaborative analysis of 18 prospective studies","volume":"100","author":"Roddam","year":"2008","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ahj.2021.11.016_bib0041","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1146\/annurev-med-050219-034711","article-title":"Benefits and risks of testosterone treatment in men with age-related decline in testosterone","volume":"72","author":"Rodrigues Dos Santos","year":"2021","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.ahj.2021.11.016_bib0042","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.juro.2018.03.115","article-title":"Evaluation and management of testosterone deficiency: AUA guideline","volume":"200","author":"Mulhall","year":"2018","journal-title":"J Urol"},{"key":"10.1016\/j.ahj.2021.11.016_bib0043","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0199194","article-title":"Testosterone treatment and the risk of aggressive prostate cancer in men with low testosterone levels","volume":"13","author":"Walsh","year":"2018","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ahj.2021.11.016_bib0044","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1093\/jnci\/dji240","article-title":"Cancer incidence and mortality in men with Klinefelter syndrome: a cohort study","volume":"97","author":"Swerdlow","year":"2005","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ahj.2021.11.016_bib0045","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1093\/gerona\/60.11.1451","article-title":"Adverse events associated with testosterone replacement in middle-aged and older men: a meta-analysis of randomized, placebo-controlled trials","volume":"60","author":"Calof","year":"2005","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"10.1016\/j.ahj.2021.11.016_bib0046","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1056\/NEJMoa1506119","article-title":"Effects of testosterone treatment in older men","volume":"374","author":"Snyder","year":"2016","journal-title":"N Engl J Med."},{"key":"10.1016\/j.ahj.2021.11.016_bib0047","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.juro.2015.10.083","article-title":"Effect of testosterone solution 2% on testosterone concentration, sex drive and energy in hypogonadal men: results of a placebo controlled study","volume":"195","author":"Brock","year":"2016","journal-title":"J Urol"},{"key":"10.1016\/j.ahj.2021.11.016_bib0048","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1210\/jc.2002-021058","article-title":"AA2500 testosterone gel normalizes androgen levels inaging males with improvements in body composition and sexual function","volume":"88","author":"Steidle","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ahj.2021.11.016_bib0049","doi-asserted-by":"crossref","first-page":"3096","DOI":"10.1210\/jc.2016-1645","article-title":"Testosterone treatment and sexual function in older men with low testosterone levels","volume":"101","author":"Cunningham","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ahj.2021.11.016_bib0050","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1001\/jamainternmed.2016.9539","article-title":"Effect of testosterone treatment on volumetric bone density and strength in older men with low testosterone: a controlled clinical trial","volume":"177","author":"Snyder","year":"2017","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.ahj.2021.11.016_bib0051","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/S2213-8587(18)30171-2","article-title":"Effect of testosterone replacement on measures of mobility in older men with mobility limitation and low testosterone concentrations: secondary analyses of the Testosterone Trials","volume":"6","author":"Bhasin","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.ahj.2021.11.016_bib0052","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1001\/jamainternmed.2016.9540","article-title":"Association of testosterone levels with anemia in older men: a controlled clinical trial","volume":"177","author":"Roy","year":"2017","journal-title":"JAMA Intern Med"}],"container-title":["American Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870321004671?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870321004671?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T06:07:33Z","timestamp":1757570853000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002870321004671"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":52,"alternative-id":["S0002870321004671"],"URL":"https:\/\/doi.org\/10.1016\/j.ahj.2021.11.016","relation":{},"ISSN":["0002-8703"],"issn-type":[{"value":"0002-8703","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of long-term testosterone treatment on cardiovascular outcomes in men with hypogonadism: Rationale and design of the TRAVERSE study","name":"articletitle","label":"Article Title"},{"value":"American Heart Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ahj.2021.11.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}